News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Lipodystrophy news

Show

From To
Neurological and cognitive problems
Fat accumulation linked to cognitive impairment in patients with HIV

Central fat accumulation is associated with an increased risk of neurocognitive impairment for HIV-positive patients, according to a study published in the February edition of Neurology. Overall 40%

Published
24 February 2012
By
Michael Carter
Lipodystrophy
Face fillers and dental work—caution needed

Reconstructive surgery to deal with the loss of subcutaneous fat in the face involved injection of facial fillers. One product used was polyalkylimide gel (PAIG, Bio-Alcamid). However, reports began to emerge from Western Europe of inflammation and infections in both HIV-negative and HIV-positive people with Bio-Alcamid implants. 

Published
25 January 2012
From
CATIE
Pharmaceutical industry
Theratechnologies to discontinue COPD clinical program and focus on lipodystrophy

The Company will now focus its efforts on tesamorelin's significant potential for the treatment of excess abdominal fat in HIV patients with lipodystrophy. Currently, applications for this indication are under review with regulatory agencies in Europe, Argentina, Brazil, Canada, Israel and Mexico.

Published
08 December 2011
From
Theratechnologies press release
Side-effects
Raltegravir kinder to bones and body fat than boosted protease inhibitors in Spanish trial

Raltegravir (Isentress)-based treatment appears to have a more favourable impact on fat accumulation and bone metabolism compared to therapy based on a ritonavir-boosted protease inhibitor, according to Spanish

Published
28 November 2011
By
Michael Carter
Ageing and HIV
Diseases of ageing occurring 10 to 15 years earlier in patients with HIV

The diseases of ageing develop earlier in patients with HIV than in the general population, Italian investigators report in the online edition of Clinical Infectious Diseases. “Our findings

Published
20 October 2011
By
Michael Carter
Cardiovascular disease
Waist circumference and triglycerides: simple measures of increased cardiovascular risk for patients with HIV

Measuring waist circumference and triglyceride levels may be an easy way of identifying which HIV-positive patients have an increased risk of cardiovascular disease, according to research published

Published
10 October 2011
By
Michael Carter
Lipodystrophy
Kivexa and Truvada-based combinations associated with long-term gains in limb fat, not fat loss

Modern antiretroviral regimens based on Kivexa and Truvada are associated with long-term gains in limb fat, US investigators report in the July 15th edition of Clinical Infectious Diseases.

Published
27 June 2011
By
Michael Carter
Lipodystrophy
Body Satisfaction Increased With Fat Gains in Prezista Study

Although treatment experienced HIV-positive men and women had slightly greater gains in trunk fat after switching to a new regimen containing Prezista (darunavir), they also reported increased satisfaction with their bodies.

Published
17 June 2011
From
AIDSMeds
Lipodystrophy
Theratechnologies seeks European marketing for lipodystrophy drug Tesamorelin

Theratechnologies Inc. says it has applied to sell its lead drug tesamorelin in Europe. The drug is a treatment for excess abdominal fat in adult HIV-infected patients with lipodystrophy.

Published
07 June 2011
From
Stock House
Cardiovascular disease
Amount of fat around the heart can predict cardiovascular risk for patients with HIV

Measuring the volume of fat around the heart can help predict which HIV-positive patients have an increased risk of cardiovascular disease, an Italian study published in the

Published
27 April 2011
By
Michael Carter
← Prev1...23456...7Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.